Experimental combo therapy for advanced breast cancer tested in small early trial

NCT ID NCT06878248

Terminated Disease control Sponsor: Calibr, a division of Scripps Research Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 28 times

Summary

This early-phase study tested a new treatment for people with advanced breast cancer that had stopped responding to standard therapies. The treatment combined a patient's own engineered immune cells (CLBR001) with an antibody drug (ABBV-461). The study aimed to find the safest dose and check for side effects, but it was terminated early after enrolling only 10 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Augusta University Medical Center

Augusta, Georgia, 30912, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, 46202, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
University of Virginia

Charlottesville, Virginia, 22908, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER, METASTATIC HER2 + BREAST CANCER HORMONE RECEPTOR-POSITIVE BREAST CANCER LOCALLY ADVANCED BREAST CANCER (LABC) MALIGNANT NEOPLASM OF BREAST TRIPLE NEGATIVE BREAST CANCER (TNBC)